Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Veterans | 34 | 2024 | 2649 | 2.280 |
Why?
|
Veterans Health | 4 | 2024 | 215 | 0.920 |
Why?
|
Allopurinol | 4 | 2024 | 198 | 0.760 |
Why?
|
Technology | 1 | 2024 | 292 | 0.760 |
Why?
|
United States Department of Veterans Affairs | 14 | 2024 | 928 | 0.660 |
Why?
|
Chlorthalidone | 3 | 2022 | 21 | 0.560 |
Why?
|
Antirheumatic Agents | 7 | 2023 | 1372 | 0.540 |
Why?
|
Gout | 4 | 2024 | 621 | 0.510 |
Why?
|
Gout Suppressants | 4 | 2024 | 177 | 0.490 |
Why?
|
Medical Oncology | 5 | 2024 | 2321 | 0.470 |
Why?
|
Multiple Myeloma | 8 | 2024 | 5146 | 0.400 |
Why?
|
Hydrochlorothiazide | 3 | 2022 | 94 | 0.390 |
Why?
|
Sulfasalazine | 3 | 2017 | 84 | 0.390 |
Why?
|
Arthritis, Rheumatoid | 7 | 2023 | 3763 | 0.360 |
Why?
|
Workflow | 4 | 2024 | 851 | 0.330 |
Why?
|
Venous Thromboembolism | 4 | 2023 | 1866 | 0.320 |
Why?
|
Lung Neoplasms | 7 | 2024 | 13382 | 0.320 |
Why?
|
Diuretics | 4 | 2023 | 610 | 0.300 |
Why?
|
Hydroxychloroquine | 3 | 2017 | 426 | 0.290 |
Why?
|
Neoplasms | 9 | 2024 | 22173 | 0.290 |
Why?
|
Natural Language Processing | 3 | 2024 | 1163 | 0.270 |
Why?
|
Methotrexate | 4 | 2017 | 1719 | 0.270 |
Why?
|
Databases, Factual | 3 | 2019 | 7967 | 0.260 |
Why?
|
United States | 40 | 2024 | 72335 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 5315 | 0.230 |
Why?
|
Warfarin | 3 | 2004 | 1483 | 0.220 |
Why?
|
Drug Hypersensitivity | 2 | 2003 | 917 | 0.220 |
Why?
|
Bipolar Disorder | 4 | 2024 | 5092 | 0.210 |
Why?
|
Phenylthiohydantoin | 1 | 2024 | 205 | 0.210 |
Why?
|
Humans | 97 | 2024 | 761572 | 0.210 |
Why?
|
Spondylitis, Ankylosing | 1 | 2023 | 155 | 0.200 |
Why?
|
Thromboplastin | 2 | 1994 | 286 | 0.200 |
Why?
|
Simvastatin | 2 | 2008 | 346 | 0.200 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1896 | 0.190 |
Why?
|
Disulfiram | 1 | 2021 | 63 | 0.190 |
Why?
|
Aphasia | 1 | 2003 | 192 | 0.190 |
Why?
|
Lisinopril | 2 | 2013 | 61 | 0.190 |
Why?
|
Algorithms | 5 | 2024 | 14032 | 0.190 |
Why?
|
Schizophrenia | 4 | 2024 | 6937 | 0.190 |
Why?
|
Patient Identification Systems | 1 | 2020 | 75 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.170 |
Why?
|
Aged | 38 | 2024 | 169310 | 0.170 |
Why?
|
Sodium Bicarbonate | 2 | 2017 | 60 | 0.170 |
Why?
|
Anticoagulants | 6 | 2020 | 4812 | 0.170 |
Why?
|
Paraproteinemias | 1 | 2022 | 248 | 0.170 |
Why?
|
Losartan | 2 | 2013 | 265 | 0.170 |
Why?
|
Genome-Wide Association Study | 4 | 2024 | 12690 | 0.160 |
Why?
|
Electronic Health Records | 8 | 2024 | 4811 | 0.160 |
Why?
|
Nitriles | 1 | 2024 | 971 | 0.160 |
Why?
|
Acute Kidney Injury | 3 | 2017 | 1924 | 0.160 |
Why?
|
Gulf War | 1 | 2018 | 33 | 0.160 |
Why?
|
Histiocytosis, Langerhans-Cell | 1 | 2000 | 169 | 0.160 |
Why?
|
Acetylcysteine | 2 | 2017 | 260 | 0.160 |
Why?
|
Hypolipidemic Agents | 1 | 2003 | 609 | 0.160 |
Why?
|
Ecosystem | 1 | 2023 | 490 | 0.160 |
Why?
|
Benzamides | 1 | 2024 | 1370 | 0.160 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2013 | 431 | 0.160 |
Why?
|
Vitamin K | 1 | 2001 | 318 | 0.150 |
Why?
|
Hiccup | 1 | 1998 | 8 | 0.150 |
Why?
|
Dementia | 2 | 2024 | 2689 | 0.150 |
Why?
|
Dexamethasone | 3 | 2023 | 1948 | 0.150 |
Why?
|
Antiviral Agents | 4 | 2024 | 3060 | 0.150 |
Why?
|
Chromatography, Liquid | 1 | 2021 | 983 | 0.150 |
Why?
|
Drug Dosage Calculations | 1 | 2018 | 117 | 0.150 |
Why?
|
Computer Security | 1 | 2019 | 261 | 0.140 |
Why?
|
Biological Products | 2 | 2017 | 914 | 0.140 |
Why?
|
Prothrombin Time | 2 | 1994 | 117 | 0.140 |
Why?
|
Male | 48 | 2024 | 360842 | 0.140 |
Why?
|
Specimen Handling | 1 | 2021 | 702 | 0.140 |
Why?
|
Prostatectomy | 2 | 2020 | 1824 | 0.140 |
Why?
|
Middle Aged | 36 | 2024 | 220920 | 0.140 |
Why?
|
Medical Informatics | 1 | 2024 | 733 | 0.140 |
Why?
|
Uric Acid | 4 | 2024 | 807 | 0.140 |
Why?
|
Research Design | 8 | 2023 | 6180 | 0.130 |
Why?
|
Hypertension | 3 | 2022 | 8540 | 0.130 |
Why?
|
Patient Care Management | 1 | 2019 | 302 | 0.130 |
Why?
|
Biological Factors | 1 | 2017 | 157 | 0.130 |
Why?
|
Medical Order Entry Systems | 2 | 2012 | 521 | 0.130 |
Why?
|
Point-of-Care Systems | 3 | 2023 | 1213 | 0.130 |
Why?
|
Virus Diseases | 1 | 2022 | 718 | 0.130 |
Why?
|
International Classification of Diseases | 1 | 2021 | 909 | 0.130 |
Why?
|
Sodium Chloride | 1 | 2017 | 587 | 0.130 |
Why?
|
Psoriasis | 1 | 2023 | 950 | 0.120 |
Why?
|
Drug Therapy, Combination | 10 | 2017 | 6312 | 0.120 |
Why?
|
Sucrose | 1 | 1995 | 158 | 0.120 |
Why?
|
Meningioma | 1 | 2024 | 1218 | 0.120 |
Why?
|
Retrospective Studies | 18 | 2024 | 80646 | 0.120 |
Why?
|
Antihypertensive Agents | 3 | 2022 | 2024 | 0.120 |
Why?
|
Randomized Controlled Trials as Topic | 6 | 2016 | 10212 | 0.120 |
Why?
|
Meningeal Neoplasms | 1 | 2024 | 1248 | 0.120 |
Why?
|
Angiography | 2 | 2017 | 1595 | 0.120 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2013 | 1516 | 0.120 |
Why?
|
Clinical Trials as Topic | 3 | 2019 | 8002 | 0.120 |
Why?
|
Mass Spectrometry | 1 | 2021 | 2192 | 0.120 |
Why?
|
Diabetic Nephropathies | 2 | 2013 | 973 | 0.120 |
Why?
|
Learning | 1 | 2024 | 1740 | 0.120 |
Why?
|
Occupational Health | 1 | 2020 | 806 | 0.110 |
Why?
|
Epidemiologic Methods | 1 | 2018 | 1336 | 0.110 |
Why?
|
Suicidal Ideation | 1 | 2024 | 1447 | 0.110 |
Why?
|
Anaphylaxis | 1 | 2001 | 757 | 0.110 |
Why?
|
Hospitals, Veterans | 4 | 2022 | 395 | 0.110 |
Why?
|
Venous Thrombosis | 1 | 2023 | 1303 | 0.110 |
Why?
|
Hodgkin Disease | 1 | 2000 | 1378 | 0.110 |
Why?
|
Prostatic Neoplasms | 4 | 2024 | 11122 | 0.110 |
Why?
|
Melanoma | 2 | 2022 | 5709 | 0.100 |
Why?
|
Female | 36 | 2024 | 392686 | 0.100 |
Why?
|
Double-Blind Method | 8 | 2024 | 12341 | 0.100 |
Why?
|
Contrast Media | 2 | 2017 | 5311 | 0.100 |
Why?
|
Anti-Inflammatory Agents | 1 | 2022 | 1809 | 0.100 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2024 | 2243 | 0.100 |
Why?
|
Antidepressive Agents | 1 | 2024 | 2897 | 0.100 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58986 | 0.100 |
Why?
|
Proteome | 1 | 2021 | 1862 | 0.100 |
Why?
|
Research Support as Topic | 1 | 2015 | 697 | 0.090 |
Why?
|
Risk Factors | 13 | 2024 | 74213 | 0.090 |
Why?
|
Immunoglobulins, Intravenous | 1 | 1995 | 664 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2013 | 585 | 0.090 |
Why?
|
Disability Evaluation | 2 | 2017 | 1836 | 0.090 |
Why?
|
Vitamin D Deficiency | 1 | 2020 | 1388 | 0.090 |
Why?
|
Software | 2 | 2023 | 4434 | 0.090 |
Why?
|
Biological Specimen Banks | 1 | 2015 | 783 | 0.090 |
Why?
|
Cohort Studies | 9 | 2023 | 41493 | 0.080 |
Why?
|
Plasma Cells | 2 | 2023 | 599 | 0.080 |
Why?
|
Peptides | 1 | 2021 | 4358 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1998 | 1520 | 0.080 |
Why?
|
Neoplasm Staging | 1 | 2024 | 11121 | 0.080 |
Why?
|
Pulmonary Embolism | 1 | 2023 | 2567 | 0.080 |
Why?
|
Inflammatory Bowel Diseases | 1 | 2023 | 2422 | 0.080 |
Why?
|
Thrombosis | 1 | 2023 | 2942 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3482 | 0.080 |
Why?
|
Information Dissemination | 1 | 2017 | 1126 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4652 | 0.080 |
Why?
|
Gastrointestinal Diseases | 1 | 2017 | 1200 | 0.080 |
Why?
|
Glucocorticoids | 1 | 1998 | 2161 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4319 | 0.080 |
Why?
|
Occupational Exposure | 1 | 2018 | 1813 | 0.080 |
Why?
|
Frail Elderly | 2 | 2023 | 765 | 0.080 |
Why?
|
Pilot Projects | 2 | 2019 | 8633 | 0.070 |
Why?
|
Proteomics | 1 | 2021 | 3848 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2024 | 64684 | 0.070 |
Why?
|
Drug Costs | 1 | 2015 | 1183 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2023 | 3615 | 0.070 |
Why?
|
Medical Records | 2 | 2023 | 1408 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2019 | 1852 | 0.070 |
Why?
|
Cost-Benefit Analysis | 2 | 2017 | 5492 | 0.070 |
Why?
|
Proportional Hazards Models | 5 | 2024 | 12463 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2024 | 13642 | 0.070 |
Why?
|
Health Personnel | 1 | 2020 | 3335 | 0.070 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1505 | 0.070 |
Why?
|
Insulin | 2 | 2012 | 6597 | 0.070 |
Why?
|
Adult | 18 | 2024 | 221203 | 0.070 |
Why?
|
Depressive Disorder, Major | 1 | 2024 | 4761 | 0.070 |
Why?
|
Early Detection of Cancer | 1 | 2021 | 3201 | 0.070 |
Why?
|
Vaccination | 3 | 2023 | 3384 | 0.070 |
Why?
|
Proteinuria | 1 | 2008 | 607 | 0.060 |
Why?
|
Cognition Disorders | 1 | 2019 | 3980 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2004 | 5127 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 1993 | 1779 | 0.060 |
Why?
|
Health Status | 1 | 2018 | 4077 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5369 | 0.060 |
Why?
|
Alanine Transaminase | 1 | 2008 | 603 | 0.060 |
Why?
|
Delivery of Health Care | 4 | 2023 | 5336 | 0.060 |
Why?
|
Taxoids | 1 | 2008 | 668 | 0.060 |
Why?
|
Glomerular Filtration Rate | 3 | 2024 | 2177 | 0.060 |
Why?
|
Incidence | 5 | 2023 | 21355 | 0.060 |
Why?
|
Genomics | 2 | 2017 | 5821 | 0.050 |
Why?
|
Androstenes | 1 | 2024 | 181 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2022 | 78 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2024 | 9031 | 0.050 |
Why?
|
Hyperglycemia | 1 | 2011 | 1376 | 0.050 |
Why?
|
Knowledge | 1 | 2024 | 177 | 0.050 |
Why?
|
Polypharmacy | 1 | 2005 | 306 | 0.050 |
Why?
|
Cognition | 1 | 2019 | 6992 | 0.050 |
Why?
|
Fatty Liver | 1 | 2008 | 790 | 0.050 |
Why?
|
Tissue Banks | 1 | 2002 | 184 | 0.050 |
Why?
|
Vitamin K Deficiency | 1 | 2001 | 24 | 0.050 |
Why?
|
Genotype | 4 | 2020 | 12990 | 0.050 |
Why?
|
Skin Neoplasms | 1 | 2021 | 5821 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2013 | 4544 | 0.050 |
Why?
|
Drug Administration Routes | 1 | 2001 | 150 | 0.050 |
Why?
|
Prognosis | 4 | 2023 | 29629 | 0.050 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2001 | 186 | 0.040 |
Why?
|
Kidney Failure, Chronic | 2 | 2013 | 2472 | 0.040 |
Why?
|
Reference Standards | 2 | 1994 | 1003 | 0.040 |
Why?
|
Jurkat Cells | 1 | 2021 | 740 | 0.040 |
Why?
|
Drug Monitoring | 2 | 2018 | 962 | 0.040 |
Why?
|
Administration, Oral | 3 | 2017 | 4021 | 0.040 |
Why?
|
Systems Integration | 1 | 2020 | 426 | 0.040 |
Why?
|
Goals | 1 | 2023 | 711 | 0.040 |
Why?
|
Comorbidity | 2 | 2021 | 10508 | 0.040 |
Why?
|
Metoclopramide | 1 | 1998 | 51 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2019 | 297 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17904 | 0.040 |
Why?
|
Pandemics | 3 | 2023 | 8656 | 0.040 |
Why?
|
Attitude | 1 | 2023 | 775 | 0.040 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.040 |
Why?
|
Ambulatory Care Facilities | 1 | 2024 | 935 | 0.040 |
Why?
|
Self-Injurious Behavior | 1 | 2024 | 566 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2018 | 10766 | 0.040 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2001 | 494 | 0.040 |
Why?
|
Blood Specimen Collection | 1 | 2018 | 238 | 0.040 |
Why?
|
Length of Stay | 1 | 2011 | 6426 | 0.040 |
Why?
|
Quality Control | 1 | 2020 | 832 | 0.040 |
Why?
|
Life Tables | 1 | 2017 | 364 | 0.040 |
Why?
|
SEER Program | 1 | 2022 | 1450 | 0.030 |
Why?
|
Dopamine Antagonists | 1 | 1998 | 288 | 0.030 |
Why?
|
Medication Therapy Management | 1 | 2018 | 130 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2002 | 783 | 0.030 |
Why?
|
Ileus | 1 | 2017 | 66 | 0.030 |
Why?
|
Vasodilation | 1 | 2001 | 962 | 0.030 |
Why?
|
Hemoglobins | 1 | 2023 | 1526 | 0.030 |
Why?
|
Blood Pressure | 2 | 2022 | 8481 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2020 | 3514 | 0.030 |
Why?
|
Drug Interactions | 1 | 2001 | 1416 | 0.030 |
Why?
|
Comparative Effectiveness Research | 2 | 2012 | 709 | 0.030 |
Why?
|
Gingival Hemorrhage | 1 | 1995 | 49 | 0.030 |
Why?
|
Prospective Studies | 5 | 2023 | 54426 | 0.030 |
Why?
|
Geriatric Assessment | 1 | 2023 | 1410 | 0.030 |
Why?
|
Multifactorial Inheritance | 1 | 2024 | 1387 | 0.030 |
Why?
|
Informed Consent | 1 | 2002 | 1008 | 0.030 |
Why?
|
Aspirin | 2 | 2002 | 3133 | 0.030 |
Why?
|
HeLa Cells | 1 | 2021 | 3094 | 0.030 |
Why?
|
Drug Prescriptions | 1 | 2005 | 1670 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2023 | 1089 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8224 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 39970 | 0.030 |
Why?
|
Gastritis | 1 | 2017 | 199 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1402 | 0.030 |
Why?
|
Sequence Analysis | 1 | 2015 | 240 | 0.030 |
Why?
|
Tumor Burden | 1 | 2021 | 1893 | 0.030 |
Why?
|
Drug Substitution | 1 | 2017 | 290 | 0.030 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2001 | 696 | 0.030 |
Why?
|
Renal Dialysis | 2 | 2017 | 1796 | 0.030 |
Why?
|
Medicare | 2 | 2023 | 6770 | 0.030 |
Why?
|
RNA, Viral | 1 | 2022 | 2846 | 0.030 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2008 | 12148 | 0.030 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 7054 | 0.030 |
Why?
|
Blotting, Western | 1 | 2021 | 5035 | 0.030 |
Why?
|
Patient Care | 1 | 2019 | 622 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1913 | 0.030 |
Why?
|
Genetic Markers | 1 | 2020 | 2601 | 0.030 |
Why?
|
Fluid Therapy | 1 | 2017 | 579 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2024 | 4915 | 0.030 |
Why?
|
Antibodies | 1 | 2021 | 2418 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5841 | 0.030 |
Why?
|
Abscess | 1 | 2017 | 606 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 2017 | 432 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2017 | 2218 | 0.030 |
Why?
|
Suicide | 1 | 2024 | 1601 | 0.030 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3245 | 0.030 |
Why?
|
Neoplasm Invasiveness | 1 | 2021 | 3597 | 0.030 |
Why?
|
Risk Assessment | 4 | 2023 | 23996 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2001 | 1664 | 0.030 |
Why?
|
Reproducibility of Results | 2 | 2021 | 20099 | 0.030 |
Why?
|
Hemorrhage | 2 | 2002 | 3424 | 0.030 |
Why?
|
Free Radical Scavengers | 1 | 2013 | 211 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4352 | 0.020 |
Why?
|
Creatinine | 1 | 2017 | 1899 | 0.020 |
Why?
|
Canada | 1 | 2017 | 2122 | 0.020 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2273 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 13367 | 0.020 |
Why?
|
ROC Curve | 1 | 2019 | 3579 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1745 | 0.020 |
Why?
|
Remission Induction | 1 | 2017 | 2397 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2297 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2019 | 3778 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2024 | 26127 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2548 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1749 | 0.020 |
Why?
|
Oxygen | 1 | 2022 | 4227 | 0.020 |
Why?
|
Bleeding Time | 1 | 1990 | 83 | 0.020 |
Why?
|
Alcoholism | 1 | 2021 | 1973 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14607 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2022 | 2630 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 2017 | 802 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1722 | 0.020 |
Why?
|
Cost Savings | 1 | 2015 | 913 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2020 | 15936 | 0.020 |
Why?
|
Body Mass Index | 1 | 2008 | 12954 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2021 | 15843 | 0.020 |
Why?
|
Pancreatitis | 1 | 2017 | 1096 | 0.020 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39107 | 0.020 |
Why?
|
Drug Industry | 1 | 2015 | 788 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1648 | 0.020 |
Why?
|
Respiratory Tract Infections | 1 | 2017 | 1010 | 0.020 |
Why?
|
Genome, Human | 1 | 2002 | 4425 | 0.020 |
Why?
|
Postoperative Care | 1 | 1995 | 1468 | 0.020 |
Why?
|
Platelet Function Tests | 1 | 1990 | 271 | 0.020 |
Why?
|
Alleles | 1 | 2019 | 6864 | 0.020 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2578 | 0.020 |
Why?
|
Health Surveys | 1 | 2018 | 4061 | 0.020 |
Why?
|
Liver | 1 | 2024 | 7529 | 0.020 |
Why?
|
Mortality | 1 | 2019 | 2901 | 0.020 |
Why?
|
Lovastatin | 1 | 2008 | 115 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9326 | 0.020 |
Why?
|
Health Behavior | 1 | 2018 | 2644 | 0.020 |
Why?
|
Treatment Failure | 1 | 2013 | 2644 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5872 | 0.020 |
Why?
|
Heart Valve Prosthesis | 1 | 1995 | 1462 | 0.020 |
Why?
|
International Cooperation | 1 | 1993 | 1422 | 0.020 |
Why?
|
Hyperkalemia | 1 | 2008 | 233 | 0.020 |
Why?
|
Data Collection | 1 | 2015 | 3322 | 0.020 |
Why?
|
Phenotype | 1 | 2024 | 16592 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.020 |
Why?
|
Pravastatin | 1 | 2008 | 392 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1192 | 0.020 |
Why?
|
Obesity | 1 | 2008 | 12947 | 0.020 |
Why?
|
Adolescent | 2 | 2024 | 88324 | 0.020 |
Why?
|
Pneumonia | 1 | 2017 | 2143 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2021 | 16986 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7827 | 0.010 |
Why?
|
Quality Improvement | 1 | 2019 | 3801 | 0.010 |
Why?
|
Young Adult | 2 | 2024 | 59255 | 0.010 |
Why?
|
Prevalence | 1 | 2021 | 15732 | 0.010 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 857 | 0.010 |
Why?
|
Bayes Theorem | 1 | 2012 | 2330 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2015 | 3688 | 0.010 |
Why?
|
Regression Analysis | 1 | 1993 | 6344 | 0.010 |
Why?
|
Environmental Exposure | 1 | 2018 | 4486 | 0.010 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 1995 | 2751 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6484 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11742 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10721 | 0.010 |
Why?
|
Age Distribution | 1 | 2008 | 2880 | 0.010 |
Why?
|
Sensitivity and Specificity | 2 | 1995 | 14666 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5440 | 0.010 |
Why?
|
Radiotherapy | 1 | 2008 | 1499 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2002 | 11461 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7391 | 0.010 |
Why?
|
Odds Ratio | 2 | 2008 | 9646 | 0.010 |
Why?
|
Anticholesteremic Agents | 1 | 2008 | 966 | 0.010 |
Why?
|
Phlebotomy | 1 | 2001 | 137 | 0.010 |
Why?
|
Body Weight | 1 | 2011 | 4618 | 0.010 |
Why?
|
Hemoptysis | 1 | 2001 | 152 | 0.010 |
Why?
|
International Normalized Ratio | 1 | 2002 | 382 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6935 | 0.010 |
Why?
|
Outpatients | 1 | 2008 | 1597 | 0.010 |
Why?
|
Patient Selection | 1 | 2012 | 4244 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30054 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2008 | 6815 | 0.010 |
Why?
|
Terminology as Topic | 1 | 2005 | 1530 | 0.010 |
Why?
|
Radiography | 1 | 2008 | 6965 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15501 | 0.010 |
Why?
|
Hematoma | 1 | 2001 | 767 | 0.010 |
Why?
|
Risk | 1 | 2008 | 9610 | 0.010 |
Why?
|
Recurrence | 1 | 2008 | 8466 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2008 | 12059 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2008 | 4235 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2020 | 21017 | 0.010 |
Why?
|
Disease Progression | 1 | 2008 | 13510 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2008 | 15266 | 0.010 |
Why?
|
Safety | 1 | 1995 | 1150 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1995 | 2927 | 0.010 |
Why?
|
Blood Coagulation Tests | 1 | 1990 | 271 | 0.010 |
Why?
|
Animals | 1 | 2001 | 168467 | 0.000 |
Why?
|
Survival Rate | 1 | 2002 | 12725 | 0.000 |
Why?
|
Platelet Aggregation | 1 | 1990 | 771 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2001 | 20571 | 0.000 |
Why?
|